key: cord-0698480-khrh289z
authors: Rothan, Hussin A.; Stone, Shannon; Natekar, Janhavi; Kumari, Pratima; Arora, Komal; Kumar, Mukesh
title: The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells
date: 2020-05-19
journal: Virology
DOI: 10.1016/j.virol.2020.05.002
sha: 520a7db4ac2aa88af438c0bc7fd742e680dc7414
doc_id: 698480
cord_uid: khrh289z

SARS-COV-2 has recently emerged as a new public health threat. Herein, we report that the FDA-approved drug, auranofin, inhibits SARS-COV-2 replication in human cells at low micro molar concentration. Treatment of cells with auranofin resulted in a 95% reduction in the viral RNA at 48 h after infection. Auranofin treatment dramatically reduced the expression of SARS-COV-2-induced cytokines in human cells. These data indicate that auranofin could be a useful drug to limit SARS-CoV-2 infection and associated lung injury due to its antiviral, anti-inflammatory and anti-reactive oxygen species (ROS) properties. Further animal studies are warranted to evaluate the safety and efficacy of auranofin for the management of SARS-COV-2 associated disease.

SARS-COV-2 has recently emerged as a new public health threat. Herein, we report 2 that the FDA-approved drug, auranofin, inhibits SARS-COV-2 replication in human 3 cells at low micro molar concentration. Treatment of cells with auranofin resulted in a 4 95% reduction in the viral RNA at 48 hours after infection. Auranofin treatment 5 dramatically reduced the expression of SARS-COV-2-induced cytokines in human 6 cells. These data indicate that auranofin could be a useful drug to limit SARS-CoV-2 7 infection and associated lung injury due to its antiviral, anti-inflammatory and anti- Gold-based compounds have shown promising activity against a wide range of 1 clinical conditions and microorganism infections. Auranofin, a gold-containing triethyl 2 phosphine, is an FDA-approved drug for the treatment of rheumatoid arthritis since 3 1985 (1). It has been investigated for potential therapeutic application in a number of 4 other diseases including cancer, neurodegenerative disorders, HIV/AIDS, parasitic 5 infections and bacterial infections (1, 2). Auranofin was approved by FDA for phase II 6 clinical trials for cancer therapy (3-5). Oral auranofin was effective in rodent models 7 of various parasitic infections (6, 7). A preclinical study showed that auranofin 8 significantly reduces HIV load in combination with antiretroviral therapy (8). A clinical 9

trial is ongoing to develop auranofin as a drug candidate to reduce the latent viral 10 reservoir in patients with HIV infection utilizing the role of auranofin in affecting 11 redox-sensitive cell death pathways (9, 10). 12

The mechanism of action of auranofin involves the inhibition of redox enzymes such 14 as thioredoxin reductase, induction of endoplasmic reticulum (ER) stress and 15 subsequent activation of the unfolded protein response (UPR) (2, 11-13). Inhibition 16 of these redox enzymes leads to cellular oxidative stress and intrinsic apoptosis (14, 17

Coronaviruses are a family of enveloped viruses with positive sense, single-stranded 1 RNA genomes (19). SARS-CoV-2, the causative agent of COVID-19, is closely 2 related to severe acute respiratory syndrome coronavirus (SARS-CoV-1) (19, 20). It 3 is known that ER stress and UPR activation contribute significantly to the viral 4 replication and pathogenesis during a coronavirus infection (21). Infection with 5 SARS-COV-1 increases the expression of the ER protein folding chaperons GRP78, 6 GRP94 and other ER stress related genes to maintain protein folding (22). Cells severe COVID-19 illness represents a devastating inflammatory lung disorder due to 16 cytokines storm that is associated with multiple organ dysfunction leading to high 17 was used to prepare drug stock). We used Huh7 cells in this study as these cells are 1 highly permissive for SARS-COV-2 replication. Cell culture supernatants and cell 2 lysates were collected at 24 and 48 hours after infection. Virus RNA copies were 3 measured by RT-PCR using two separate primers specific for the viral N1 gene and 4 N2 gene (27, 28). As depicted in Figure 1 , treatment of cells with auranofin resulted 5 in a 70% reduction in the viral RNA in the supernatant compared to the DMSO at 24 6 hours after infection. At 48 hours, there was an 85% reduction in the viral RNA in the 7 supernatant compared to the DMSO. Similarly, the levels of intracellular viral RNA 8 decreased by 85% at 24 hours and 95% at 48 hours in auranofin-treated cells 9

compared to the DMSO-treated cells. Both set of primers showed nearly identical 10 results. We next assayed virus titers in cell culture supernatants by plaque assay. 11

Treatment with auranofin significantly reduced SARS-COV-2 infectivity titers in cell 12 culture supernatants at 48 hours after infection (Fig. 1) . Taken together these results demonstrate that auranofin inhibits replication of 9 SARS-COV-2 in human cells at low micro molar concentration. We also demonstrate 10 that auranofin treatment resulted in significant reduction in the expression of 11 cytokines induced by virus infection. These data indicate that auranofin could be a 12 useful drug to limit SARS-CoV-2 infection and associated lung injury. Further animal 1 studies are warranted to evaluate the safety and efficacy of auranofin for the 2 management of SARS-COV-2 associated disease. 3 4 Methods 5

In this study, we used a novel SARS-COV-2 (USA-WA1/2020) isolated from an 7 oropharyngeal swab from a patient in Washington, USA (BEI NR-52281). Virus strain 8 was amplified once in Vero E6 cells and had titers of 5 X 10 6 plaque-forming units 

Virus infectivity titers were measured in cell culture supernatants by plaque formation 22 assay using Vero cells as we described previously (31) . Virus RNA levels were 23 analyzed in the supernatant and cell lysates by quantitative reverse transcription-extracted using a Viral RNA Mini Kit (Qiagen) and RNA from cell lysates was 1 extracted using a RNeasy Mini Kit (Qiagen) as described previously (31) . The 2 cellular RNA extracted from infected cells was quantified, normalized and viral RNA 3 levels per ug of total cellular RNA were calculated. qRT-PCR was used to measure 4 viral RNA levels using previously published primers and probes specific for the For mRNA analysis of IL-6, IL-1β, TNFα and NF-kB, cDNA was prepared from RNA 17 isolated from the cell lysates using a iScript™ cDNA Synthesis Kit (Bio-Rad, 18

Hercules, CA, USA), and qRT-PCR was conducted as described previously (31) . 19

The fold change in infected cells compared to corresponding controls was calculated 20 after normalizing to the GAPDH gene. The primer sequences used for qRT-PCR are 21 listed in Table 1 . 

• Auranofin inhibits replication of SARS-COV-2, the causative agent of COVID-19, in human cells at low micro molar concentration.

• Auranofin treatment resulted in significant reduction in SARS-COV-2-induced

Auranofin: repurposing an old drug for a golden new age

Auranofin exerts broad-spectrum bactericidal 13 activities by targeting thiol-redox homeostasis

Auranofin, an anti-rheumatic gold compound, modulates 12 apoptosis by elevating the intracellular calcium concentration ([ca2+]I) in mcf-7 13 breast cancer cells